FolioLanternBeta
MPLTMapLight Therapeutics, Inc.

James Lillie

Chief Scientific Officer at MapLight Therapeutics, Inc., as of Aug 19, 2026Sold $2.6M of stock in the past 12 months: 69% under a disclosed plan and 31% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
210K
shares held after the latest filing, MapLight Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
97K
shares sold, past 12 months
10
days with sales
$714K
largest single day, May 6, 2026
1
company filed for

Share of stake sold at MapLight Therapeutics, Inc. is not shown: the holdings do not reconcile with the filings. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMarApr 2026: $123K to cover taxesAprMay 2026: $1.5M under a disclosed plan$1.5MMayJunJul 2026: $674K to cover taxesJulAug 2026: $277K under a disclosed planAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
MapLight Therapeutics, Inc. (MPLT)Chief Scientific OfficerOct 27, 2025Aug 19, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.